


Claims

1. A compound of formula (I),



the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

10 n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended;

t is 0, 1, 2, 3 or 4 and when t is 0 then a direct bond is intended;

each Q is nitrogen or $\text{---C}\equiv$;

15 each X is nitrogen or $\text{---C}\equiv$;

each Y is nitrogen or $\text{---C}\equiv$;

20 each Z is nitrogen or $\text{---CH}\equiv$;

R^1 is $\text{---C(O)NR}^8\text{R}^9$, ---N(H)C(O)R^{10} , $\text{---C(O)---C}_{1-6}\text{alkanediylSR}^{10}$, $\text{---NR}^{11}\text{C(O)N(OH)R}^{10}$, $\text{---NR}^{11}\text{C(O)C}_{1-6}\text{alkanediylSR}^{10}$, $\text{---NR}^{11}\text{C(O)C=N(OH)R}^{10}$ or another Zn-chelating-group

25 wherein R^8 and R^9 are each independently selected from hydrogen, hydroxy, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, amino C_{1-6} alkyl or aminoaryl;

R^{10} is independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkylcarbonyl, aryl C_{1-6} alkyl, C_{1-6} alkylpyrazinyl, pyridinone, pyrrolidinone or methylimidazolyl;

R^{11} is independently selected from hydrogen or C_{1-6} alkyl;

30 R^2 is hydrogen, halo, hydroxy, amino, nitro, C_{1-6} alkyl, C_{1-6} alkyloxy, trifluoromethyl, di(C_{1-6} alkyl)amino, hydroxyamino or naphthalenylsulfonylpyrazinyl;

35 each R^3 independently represents a hydrogen atom and one hydrogen atom can be replaced by a substituent selected from aryl;


R^4 is hydrogen, hydroxy, amino, hydroxy C_{1-6} alkyl, C_{1-6} alkyl, C_{1-6} alkyloxy, aryl C_{1-6} alkyl, aminocarbonyl, hydroxycarbonyl, amino C_{1-6} alkyl, aminocarbonyl C_{1-6} alkyl, hydroxycarbonyl C_{1-6} alkyl, hydroxyaminocarbonyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylamino C_{1-6} alkyl or di(C_{1-6} alkyl)amino C_{1-6} alkyl;

5


R^5 is hydrogen, C_{1-6} alkyl, C_{3-10} cycloalkyl, hydroxy C_{1-6} alkyl, C_{1-6} alkyloxy C_{1-6} alkyl, di(C_{1-6} alkyl)amino C_{1-6} alkyl or aryl;

— is a radical selected from


10




(a-1)




(a-2)




(a-3)




(a-4)




(a-5)




(a-6)




(a-7)




(a-8)




(a-9)



(a-10)




(a-11)




(a-12)


15




(a-13)











(a-14)















(a-15)







(a-16)




5




10







(a-41)




(a-42)




(a-43)




(a-44)




(a-45)




(a-46)




(a-47)




(a-48)



(a-49)



(a-50)



(a-51)

5

wherein each s is independently 0, 1, 2, 3, 4 or 5;

each R^6 and R^7 are independently selected from hydrogen; halo; hydroxy; amino; nitro;

trihaloC₁₋₆alkyl; trihaloC₁₋₆alkyloxy; C₁₋₆alkyl; C₁₋₆alkyl substituted with aryl and

C₃₋₁₀cycloalkyl; C₁₋₆alkyloxy; C₁₋₆alkyloxyC₁₋₆alkyloxy; C₁₋₆alkylcarbonyl;

10 C₁₋₆alkyloxycarbonyl; C₁₋₆alkylsulfonyl; cyanoC₁₋₆alkyl; hydroxyC₁₋₆alkyl;

hydroxyC₁₋₆alkyloxy; hydroxyC₁₋₆alkylamino; aminoC₁₋₆alkyloxy;

di(C₁₋₆alkyl)aminocarbonyl; di(hydroxyC₁₋₆alkyl)amino; (aryl)(C₁₋₆alkyl)amino;

di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy; di(C₁₋₆alkyl)aminoC₁₋₆alkylamino;

di(C₁₋₆alkyl)aminoC₁₋₆alkylaminoC₁₋₆alkyl; arylsulfonyl; arylsulfonylamino;

15 aryloxy; aryloxyC₁₋₆alkyl; arylC₂₋₆alkenediyl; di(C₁₋₆alkyl)amino;

di(C₁₋₆alkyl)aminoC₁₋₆alkyl; di(C₁₋₆alkyl)amino(C₁₋₆alkyl)amino;

di(C₁₋₆alkyl)amino(C₁₋₆alkyl)aminoC₁₋₆alkyl;

di(C₁₋₆alkyl)aminoC₁₋₆alkyl(C₁₋₆alkyl)amino;

di(C₁₋₆alkyl)aminoC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl;

20 aminosulfonylamino(C₁₋₆alkyl)amino;

aminosulfonylamino(C₁₋₆alkyl)aminoC₁₋₆alkyl;

di(C₁₋₆alkyl)aminosulfonylamino(C₁₋₆alkyl)amino;

di(C₁₋₆alkyl)aminosulfonylamino(C₁₋₆alkyl)aminoC₁₋₆alkyl; cyano; thiophenyl;

thiophenyl substituted with di(C₁₋₆alkyl)aminoC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl;

25 di(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkylpiperazinylC₁₋₆alkyl,

hydroxyC₁₋₆alkylpiperazinylC₁₋₆alkyl,

hydroxyC₁₋₆alkyloxyC₁₋₆alkylpiperazinylC₁₋₆alkyl,

- di(C₁₋₆alkyl)aminosulfonylpiperazinylC₁₋₆alkyl,
 C₁₋₆alkyloxy piperidinyl, C₁₋₆alkyloxy piperidinylC₁₋₆alkyl, morpholinylC₁₋₆alkyl,
 hydroxyC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl, or di(hydroxyC₁₋₆alkyl)aminoC₁₋₆alkyl;
 furanyl; furanyl substituted with hydroxyC₁₋₆alkyl; benzofuranyl; imidazolyl;
 5 oxazolyl; oxazolyl substituted with aryl and C₁₋₆alkyl; C₁₋₆alkyltriazolyl; tetrazolyl;
 pyrrolidinyl; pyrrolyl; piperidinylC₁₋₆alkyloxy; morpholinyl; C₁₋₆alkylmorpholinyl;
 morpholinylC₁₋₆alkyloxy; morpholinylC₁₋₆alkyl; morpholinylC₁₋₆alkylamino;
 morpholinylC₁₋₆alkylaminoC₁₋₆alkyl; piperazinyl; C₁₋₆alkylpiperazinyl;
 C₁₋₆alkylpiperazinylC₁₋₆alkyloxy; piperazinylC₁₋₆alkyl;
 10 naphthalenylsulfonylpiperazinyl; naphthalenylsulfonylpiperidinyl; naphthalenylsulfonyl;
 C₁₋₆alkylpiperazinylC₁₋₆alkyl; C₁₋₆alkylpiperazinylC₁₋₆alkylamino;
 C₁₋₆alkylpiperazinylC₁₋₆alkylaminoC₁₋₆alkyl; C₁₋₆alkylpiperazinylsulfonyl;
 aminosulfonylpiperazinylC₁₋₆alkyloxy; aminosulfonylpiperazinyl;
 aminosulfonylpiperazinylC₁₋₆alkyl; di(C₁₋₆alkyl)aminosulfonylpiperazinyl;
 15 di(C₁₋₆alkyl)aminosulfonylpiperazinylC₁₋₆alkyl; hydroxyC₁₋₆alkylpiperazinyl;
 hydroxyC₁₋₆alkylpiperazinylC₁₋₆alkyl; C₁₋₆alkyloxy piperidinyl;
 C₁₋₆alkyloxy piperidinylC₁₋₆alkyl; piperidinylaminoC₁₋₆alkylamino;
 piperidinylaminoC₁₋₆alkylaminoC₁₋₆alkyl;
 (C₁₋₆alkylpiperidinyl)(hydroxyC₁₋₆alkyl)aminoC₁₋₆alkylamino;
 20 (C₁₋₆alkylpiperidinyl)(hydroxyC₁₋₆alkyl)aminoC₁₋₆alkylaminoC₁₋₆alkyl;
 hydroxyC₁₋₆alkyloxyC₁₋₆alkylpiperazinyl;
 hydroxyC₁₋₆alkyloxyC₁₋₆alkylpiperazinylC₁₋₆alkyl;
 (hydroxyC₁₋₆alkyl)(C₁₋₆alkyl)amino; (hydroxyC₁₋₆alkyl)(C₁₋₆alkyl)aminoC₁₋₆alkyl;
 hydroxyC₁₋₆alkylaminoC₁₋₆alkyl; di(hydroxyC₁₋₆alkyl)aminoC₁₋₆alkyl;
 25 pyrrolidinylC₁₋₆alkyl; pyrrolidinylC₁₋₆alkyloxy; pyrazolyl; thiopyrazolyl; pyrazolyl
 substituted with two substituents selected from C₁₋₆alkyl or trihaloC₁₋₆alkyl;
 pyridinyl; pyridinyl substituted with C₁₋₆alkyloxy, aryloxy or aryl; pyrimidinyl;
 tetrahydropyrimidinylpiperazinyl; tetrahydropyrimidinylpiperazinylC₁₋₆alkyl;
 quinolinyl; indole; phenyl; phenyl substituted with one, two or three substituents
 30 independently selected from halo, amino, nitro, C₁₋₆alkyl, C₁₋₆alkyloxy,
 hydroxyC₁₋₄alkyl, trifluoromethyl, trifluoromethyloxy, hydroxyC₁₋₄alkyloxy,
 C₁₋₄alkylsulfonyl, C₁₋₄alkyloxyC₁₋₄alkyloxy, C₁₋₄alkyloxycarbonyl,
 aminoC₁₋₄alkyloxy, di(C₁₋₄alkyl)aminoC₁₋₄alkyloxy, di(C₁₋₄alkyl)amino,
 di(C₁₋₄alkyl)aminocarbonyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl,
 35 di(C₁₋₄alkyl)aminoC₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)amino(C₁₋₄alkyl)amino,
 di(C₁₋₄alkyl)amino(C₁₋₄alkyl)aminoC₁₋₄alkyl,
 di(C₁₋₄alkyl)aminoC₁₋₄alkyl(C₁₋₄alkyl)amino,
 di(C₁₋₄alkyl)aminoC₁₋₄alkyl(C₁₋₄alkyl)aminoC₁₋₄alkyl,


- aminosulfonylamino(C₁₋₄alkyl)amino,
 aminosulfonylamino(C₁₋₄alkyl)aminoC₁₋₄alkyl,
 di(C₁₋₄alkyl)aminosulfonylamino(C₁₋₄alkyl)amino,
 di(C₁₋₄alkyl)aminosulfonylamino(C₁₋₄alkyl)aminoC₁₋₆alkyl, cyano,
 5 piperidinylC₁₋₄alkyloxy, pyrrolidinylC₁₋₄alkyloxy, aminosulfonylpiperazinyl,
 aminosulfonylpiperazinylC₁₋₄alkyl, di(C₁₋₄alkyl)aminosulfonylpiperazinyl,
 di(C₁₋₄alkyl)aminosulfonylpiperazinylC₁₋₄alkyl, hydroxyC₁₋₄alkylpiperazinyl,
 hydroxyC₁₋₄alkylpiperazinylC₁₋₄alkyl, C₁₋₄alkyloxypiperidinyl,
 C₁₋₄alkyloxypiperidinylC₁₋₄alkyl, hydroxyC₁₋₄alkyloxyC₁₋₄alkylpiperazinyl,
 10 hydroxyC₁₋₄alkyloxyC₁₋₄alkylpiperazinylC₁₋₄alkyl,
 (hydroxyC₁₋₄alkyl)(C₁₋₄alkyl)amino, (hydroxyC₁₋₄alkyl)(C₁₋₄alkyl)aminoC₁₋₄alkyl,
 di(hydroxyC₁₋₄alkyl)amino, di(hydroxyC₁₋₄alkyl)aminoC₁₋₄alkyl, furanyl, furanyl
 substituted with -CH=CH-CH=CH-, pyrrolidinylC₁₋₄alkyl, pyrrolidinylC₁₋₄alkyloxy,
 morpholinyl, morpholinylC₁₋₄alkyloxy, morpholinylC₁₋₄alkyl,
 15 morpholinylC₁₋₄alkylamino, morpholinylC₁₋₄alkylaminoC₁₋₄alkyl, piperazinyl,
 C₁₋₄alkylpiperazinyl, C₁₋₄alkylpiperazinylC₁₋₄alkyloxy, piperazinylC₁₋₄alkyl,
 C₁₋₄alkylpiperazinylC₁₋₄alkyl, C₁₋₄alkylpiperazinylC₁₋₄alkylamino,
 C₁₋₄alkylpiperazinylC₁₋₄alkylaminoC₁₋₆alkyl, tetrahydropyrimidinylpiperazinyl,
 tetrahydropyrimidinylpiperazinylC₁₋₄alkyl, piperidinylaminoC₁₋₄alkylamino,
 20 piperidinylaminoC₁₋₄alkylaminoC₁₋₄alkyl,
 (C₁₋₄alkylpiperidinyl)(hydroxyC₁₋₄alkyl)aminoC₁₋₄alkylamino,
 (C₁₋₄alkylpiperidinyl)(hydroxyC₁₋₄alkyl)aminoC₁₋₄alkylaminoC₁₋₄alkyl,
 pyridinylC₁₋₄alkyloxy, hydroxyC₁₋₄alkylamino, hydroxyC₁₋₄alkylaminoC₁₋₄alkyl,
 di(C₁₋₄alkyl)aminoC₁₋₄alkylamino, aminothiadiazolyl,
 25 aminosulfonylpiperazinylC₁₋₄alkyloxy, or thiophenylC₁₋₄alkylamino;
 each R⁶ and R⁷ can be placed on the nitrogen in replacement of the hydrogen;

aryl in the above is phenyl, or phenyl substituted with one or more substituents each
 independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, trifluoromethyl, cyano or
 30 hydroxycarbonyl.


2. A compound as claimed in claim 1 wherein n is 0, 1 or 2; t is 0, 1, 2 or 3; each Q is
 $\text{---}\text{C}\begin{smallmatrix} \diagup \\ \diagdown \end{smallmatrix} \text{---}$; R¹ is -C(O)NH(OH) or -NR¹¹C(O)C=N(OH)R¹⁰ wherein R¹⁰ is
 arylC₁₋₆alkyl and R¹¹ is hydrogen; R² is hydrogen, C₁₋₆alkyl or
 35 naphthalenylsulfonylpiperazinyl; each R³ independently represents a hydrogen atom;
 R⁴ is hydrogen, hydroxy, hydroxyC₁₋₆alkyl or C₁₋₆alkyloxy; R⁵ is hydrogen, C₁₋₆
 alkyl, hydroxyC₁₋₆alkyl or C₁₋₆alkyloxyC₁₋₆alkyl; $\text{---}\text{A}$ is a radical selected

from (a-1), (a-7) or (a-20); each s is independently 0 or 1; each R^6 is independently selected from hydrogen; thiophenyl; furanyl; benzofuranyl; phenyl; or phenyl substituted with one substituent independently selected from C_{1-6} alkyl, C_{1-6} alkyloxy, hydroxy C_{1-4} alkyl, C_{1-4} alkylsulfonyl or di(C_{1-4} alkyl)amino and each













5 R^7 is independently selected from hydrogen.







3. A compound according to claim 1 wherein t is 0;
 R^1 is $-C(O)NR^8R^9$, $-C(O)-C_{1-6}$ alkanediylSR¹⁰, $-NR^{11}C(O)N(OH)R^{10}$,
 $-NR^{11}C(O)C_{1-6}$ alkanediylSR¹⁰, $-NR^{11}C(O)C=N(OH)R^{10}$ or another Zn-chelating-
 10 group wherein R^8 and R^9 are each independently selected from hydrogen, hydroxy, hydroxy C_{1-6} alkyl or amino C_{1-6} alkyl;
 R^2 is hydrogen, halo, hydroxy, amino, nitro, C_{1-6} alkyl, C_{1-6} alkyloxy, trifluoromethyl or di(C_{1-6} alkyl)amino;
 R^4 is hydrogen, hydroxy, amino, hydroxy C_{1-6} alkyl, C_{1-6} alkyl,
 15 C_{1-6} alkyloxy, aryl C_{1-6} alkyl, aminocarbonyl, amino C_{1-6} alkyl, C_{1-6} alkylamino C_{1-6} alkyl or di(C_{1-6} alkyl)amino C_{1-6} alkyl;
 R^5 is hydrogen;
 — is a radical selected from
 (a-1), (a-3), (a-4), (a-5), (a-6), (a-7), (a-8), (a-9), (a-10), (a-11), (a-12), (a-13), (a-14),
 20 (a-15), (a-16), (a-17), (a-18), (a-19), (a-20), (a-21), (a-22), (a-23), (a-24), (a-25), (a-26), (a-28), (a-29), (a-30), (a-31), (a-32), (a-33), (a-34), (a-35), (a-36), (a-37), (a-38), (a-39), (a-40), (a-41), (a-42), (a-44), (a-45), (a-46), (a-47), (a-48) or (a-51);
 each s is independently 0, 1, 2, 3 or 4;
 R^6 is hydrogen; halo; hydroxy; amino; nitro; trihalo C_{1-6} alkyl; trihalo C_{1-6} alkyloxy;
 25 C_{1-6} alkyl; C_{1-6} alkyloxy; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkylsulfonyl; hydroxy C_{1-6} alkyl; aryloxy; di(C_{1-6} alkyl)amino; cyano; thiophenyl; furanyl; furanyl substituted with hydroxy C_{1-6} alkyl; benzofuranyl; imidazolyl; oxazolyl; oxazolyl substituted with aryl and C_{1-6} alkyl;
 C_{1-6} alkyltriazolyl; tetrazolyl; pyrrolidinyl; pyrrolyl; morpholinyl;
 30 C_{1-6} alkylmorpholinyl; piperazinyl; C_{1-6} alkylpiperazinyl; hydroxy C_{1-6} alkylpiperazinyl; C_{1-6} alkyloxypiperidinyl; pyrazolyl; pyrazolyl substituted with one or two substituents selected from C_{1-6} alkyl or trihalo C_{1-6} alkyl; pyridinyl; pyridinyl substituted with C_{1-6} alkyloxy, aryloxy or aryl; pyrimidinyl; quinolinyl; indole; phenyl; or phenyl substituted with one or two substituents
 35 independently selected from halo, C_{1-6} alkyl, C_{1-6} alkyloxy or trifluoromethyl; and
 R^7 is hydrogen; halo; hydroxy; amino; nitro; trihalo C_{1-6} alkyl; trihalo C_{1-6} alkyloxy; C_{1-6} alkyl; C_{1-6} alkyloxy; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkylsulfonyl;

hydroxyC₁₋₆alkyl; aryloxy; di(C₁₋₆alkyl)amino; cyano; pyridinyl; phenyl; or phenyl substituted with one or two substituents independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trifluoromethyl.

- 5 4. A compound as claimed in claim 1 wherein
 R⁸ and R⁹ are each independently selected from hydrogen, hydroxy,
 hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl or aminoaryl;
 R⁵ is hydrogen, C₁₋₆alkyl, C₃₋₁₀cycloalkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl or
 di(C₁₋₆alkyl)aminoC₁₋₆alkyl;
- 10  is a radical selected from (a-1), (a-2), (a-3), (a-4), (a-5), (a-6), (a-7), (a-8),
 (a-9), (a-10), (a-11), (a-12), (a-13), (a-14), (a-15), (a-16), (a-17), (a-18), (a-19),
 (a-20), (a-21), (a-22), (a-23), (a-24), (a-25), (a-26), (a-27), (a-28), (a-29), (a-30),
 (a-31), (a-32), (a-33), (a-34), (a-35), (a-36), (a-37), (a-38), (a-39), (a-40), (a-41),
 (a-42) (a-43) or (a-44);
- 15 each R⁶ and R⁷ are independently selected from hydrogen; halo; hydroxy; amino; nitro;
 trihaloC₁₋₆alkyl; trihaloC₁₋₆alkyloxy; C₁₋₆alkyl; C₁₋₆alkyloxy;
 C₁₋₆alkyloxyC₁₋₆alkyloxy; C₁₋₆alkylcarbonyl; C₁₋₆alkylsulfonyl; cyanoC₁₋₆alkyl;
 hydroxyC₁₋₆alkyl; hydroxyC₁₋₆alkyloxy; hydroxyC₁₋₆alkylamino;
 aminoC₁₋₆alkyloxy; di(C₁₋₆alkyl)aminocarbonyl; di(hydroxyC₁₋₆alkyl)amino;
 20 arylC₁₋₆alkyl)amino; di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy;
 di(C₁₋₆alkyl)aminoC₁₋₆alkylamino; arylsulfonyl; arylsulfonylamino;
 aryloxy; arylC₂₋₆alkenediyl; di(C₁₋₆alkyl)amino;
 di(C₁₋₆alkyl)aminoC₁₋₆alkyl; di(C₁₋₆alkyl)aminoC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl;
 cyano; thiophenyl; thiophenyl substituted with
 25 di(C₁₋₆alkyl)aminoC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl, di(C₁₋₆alkyl)aminoC₁₋₆alkyl,
 C₁₋₆alkylpiperazinylC₁₋₆alkyl or di(hydroxyC₁₋₆alkyl)aminoC₁₋₆alkyl; furanyl;
 imidazolyl; C₁₋₆alkyltriazolyl; tetrazolyl; pyrrolidinyl; piperidinylC₁₋₆alkyloxy;
 morpholinyl; C₁₋₆alkylmorpholinyl; morpholinylC₁₋₆alkyloxy;
 morpholinylC₁₋₆alkyl; C₁₋₆alkylpiperazinyl; C₁₋₆alkylpiperazinylC₁₋₆alkyloxy;
 30 C₁₋₆alkylpiperazinylC₁₋₆alkyl; C₁₋₆alkylpiperazinylsulfonyl;
 aminosulfonylpiperazinylC₁₋₆alkyloxy; aminosulfonylpiperazinyl;
 aminosulfonylpiperazinylC₁₋₆alkyl; di(C₁₋₆alkyl)aminosulfonylpiperazinyl;
 di(C₁₋₆alkyl)aminosulfonylpiperazinylC₁₋₆alkyl; hydroxyC₁₋₆alkylpiperazinyl;
 hydroxyC₁₋₆alkylpiperazinylC₁₋₆alkyl; C₁₋₆alkyloxypiperidinyl;
 35 C₁₋₆alkyloxypiperidinylC₁₋₆alkyl; hydroxyC₁₋₆alkyloxyC₁₋₆alkylpiperazinyl;
 hydroxyC₁₋₆alkyloxyC₁₋₆alkylpiperazinylC₁₋₆alkyl;


- (hydroxyC₁₋₆alkyl)(C₁₋₆alkyl)amino; (hydroxyC₁₋₆alkyl)(C₁₋₆alkyl)aminoC₁₋₆alkyl; pyrrolidinylC₁₋₆alkyloxy; pyrazolyl; thiopyrazolyl; pyrazolyl substituted with two substituents selected from C₁₋₆alkyl or trihaloC₁₋₆alkyl; pyridinyl; pyridinyl substituted with C₁₋₆alkyloxy or aryl; pyrimidinyl; quinolinyl; indole; phenyl; phenyl substituted with one, two or three substituents independently selected from halo, amino, C₁₋₆alkyl, C₁₋₆alkyloxy, hydroxyC₁₋₄alkyl, trifluoromethyl, trifluoromethyloxy, hydroxyC₁₋₄alkyloxy, C₁₋₄alkyloxyC₁₋₄alkyloxy, aminoC₁₋₄alkyloxy, di(C₁₋₄alkyl)aminoC₁₋₄alkyloxy, di(C₁₋₄alkyl)amino, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl(C₁₋₄alkyl)aminoC₁₋₄alkyl, piperidinylC₁₋₄alkyloxy, pyrrolidinylC₁₋₄alkyloxy, aminosulfonylpiperazinyl, aminosulfonylpiperazinylC₁₋₄alkyl, di(C₁₋₄alkyl)aminosulfonylpiperazinyl, di(C₁₋₄alkyl)aminosulfonylpiperazinylC₁₋₄alkyl, hydroxyC₁₋₄alkylpiperazinyl, hydroxyC₁₋₄alkylpiperazinylC₁₋₄alkyl, C₁₋₄alkyloxypiperidinyl, C₁₋₄alkyloxypiperidinylC₁₋₄alkyl, hydroxyC₁₋₄alkyloxyC₁₋₄alkylpiperazinyl, hydroxyC₁₋₄alkyloxyC₁₋₄alkylpiperazinylC₁₋₄alkyl, (hydroxyC₁₋₄alkyl)(C₁₋₄alkyl)amino, (hydroxyC₁₋₄alkyl)(C₁₋₄alkyl)aminoC₁₋₄alkyl, pyrrolidinylC₁₋₄alkyloxy, morpholinylC₁₋₄alkyloxy, morpholinylC₁₋₄alkyl, C₁₋₄alkylpiperazinyl, C₁₋₄alkylpiperazinylC₁₋₄alkyloxy, C₁₋₄alkylpiperazinylC₁₋₄alkyl, hydroxyC₁₋₄alkylamino, di(hydroxyC₁₋₄alkyl)amino, di(C₁₋₄alkyl)aminoC₁₋₄alkylamino, aminothiadiazolyl, aminosulfonylpiperazinylC₁₋₄alkyloxy, or thiophenylC₁₋₄alkylamino.
5. A compound as claimed in claim 1 and 2 wherein n is 1 or 2; t is 0, 1, 2 or 3; each Q is $\text{---}\text{C}\begin{smallmatrix} \diagup \\ \diagdown \end{smallmatrix} \text{---}$; R¹ is -C(O)NH(OH); R² is hydrogen or C₁₋₆alkyl; each R³ independently represents a hydrogen atom; R⁴ is hydrogen; R⁵ is hydrogen or C₁₋₆alkyloxyC₁₋₆alkyl; $\text{---}\text{A}\cdot$ is a radical selected from (a-1) or (a-20); each s is independently 0 or 1; and each R⁶ is independently selected from hydrogen; thiophenyl; furanyl; benzofuranyl; phenyl; or phenyl substituted with one substituent independently selected from C₁₋₆alkyl, C₁₋₆alkyloxy, hydroxyC₁₋₄alkyl or di(C₁₋₄alkyl)amino.
6. A compound according to claim 1, 2 and 5 selected from compounds No. 13, No. 15, No. 2, No. 5, No. 21, No. 4, No. 24, No. 32, No. 26, No. 36, No. 38, No. 39, No. 40, No. 41, No. 42, No. 43, No. 44 and No. 35.

	
Co. No. 13	Co. No. 15
	
Co. No. 2	Co. No. 5
	
.0.7 CH ₃ OH; Co. No. 21	Co. No. 4
	
.0.23 C ₆ H ₁₄ O; Co. No. 24	.0.82 C ₂ HF ₃ O ₂ .0.82 H ₂ O; Co. No. 32
	
.0.85 C ₂ HF ₃ O ₂ .1.11 H ₂ O; Co. No. 26	Co. No. 36
	
Co. No. 38	Co. No. 39

	
Co. No. 40	Co. No. 41
	
Co. No. 42	Co. No. 43
	
Co. No. 44	Co. No. 35

7. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 1 to 6.
8. A process of preparing a pharmaceutical composition as claimed in claim 7 wherein the pharmaceutically acceptable carriers and a compound as claimed in claim 1 to 6 are intimately mixed.
9. A compound as claimed in any of claims 1 to 6 for use as a medicine.
10. Use of a compound as claimed in any of claims 1 to 6 for the manufacture of a medicament for the treatment of proliferative diseases.
11. A process for preparing a compound as claimed in claim 1, characterized by reacting an intermediate of formula (II) with an appropriate acid, such as for example, trifluoro acetic acid, yielding a hydroxamic acid of formula (I-a), wherein R¹ is -C(O)NH(OH)

-88-



12. A method of detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC.
13. A combination of an anti-cancer agents and a HDAC inhibitor as claimed in any of claims 1 to 6.